AbCellera Biologics Inc [NASDAQ: ABCL] stock went on an upward path that rose over 4.26% on Thursday, amounting to a one-week price decrease of less than -4.37%.
Over the last 12 months, ABCL stock rose by 41.98%. The one-year AbCellera Biologics Inc stock forecast points to a potential upside of 55.41. The average equity rating for ABCL stock is currently 1.25, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.24 billion, with 298.65 million shares outstanding and 225.43 million shares in the current float. Compared to the average trading volume of 6.46M shares, ABCL stock reached a trading volume of 7179628 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on AbCellera Biologics Inc [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $9.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for AbCellera Biologics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 07, 2025. The new note on the price target was released on August 20, 2024, representing the official price target for AbCellera Biologics Inc stock. Previously, the target price had yet another raise to $9, while The Benchmark Company analysts kept a Buy rating on ABCL stock.
The Price to Book ratio for the last quarter was 1.23, with the Price to Cash per share for the same quarter was set at 1.93.
ABCL Stock Performance Analysis:
AbCellera Biologics Inc [ABCL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.37. With this latest performance, ABCL shares dropped by -4.59% in over the last four-week period, additionally plugging by 74.06% over the last 6 months – not to mention a rise of 41.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 47.06, with the RSI for the last a single of trading hit 0.30, and the three-weeks RSI is set at 0.32 for AbCellera Biologics Inc [ABCL]. The present Moving Average for the last 50 days of trading for this stock 4.28, while it was recorded at 4.14 for the last single week of trading, and 3.09 for the last 200 days.
Insight into AbCellera Biologics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AbCellera Biologics Inc [ABCL] shares currently have an operating margin of -847.62% and a Gross Margin at -100.33%. AbCellera Biologics Inc’s Net Margin is presently recorded at -503.91%.
AbCellera Biologics Inc (ABCL) Capital Structure & Debt Analysis
According to recent financial data for AbCellera Biologics Inc. ( ABCL), the Return on Equity (ROE) stands at -15.64%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -11.77%, reflecting the company’s efficiency in generating profits from its assets. Additionally, AbCellera Biologics Inc’s Return on Invested Capital (ROIC) is -14.48%, showcasing its effectiveness in deploying capital for earnings.
AbCellera Biologics Inc (ABCL) Efficiency & Liquidity Metrics
Based on AbCellera Biologics Inc’s (ABCL) latest financial statements, the Debt-to-Equity Ratio is 0.14%, indicating its reliance on debt financing relative to shareholder equity.
AbCellera Biologics Inc (ABCL) Efficiency & Liquidity Metrics
From an operational efficiency perspective, AbCellera Biologics Inc. (ABCL) effectively leverages its workforce, generating an average of -$277969.8 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.07% and a Quick Ratio of 11.07%, indicating strong ability to cover short-term liabilities.
ABCL Stock EPS
With the latest financial reports released by the company, AbCellera Biologics Inc posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc go to 4.74%.
AbCellera Biologics Inc [ABCL] Institutonal Ownership Details
There are presently around $38.47%, or 49.92%% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: BAKER BROS. ADVISORS LP with ownership of 27.53 million shares, which is approximately 9.3556%. BAILLIE GIFFORD & CO, holding 21.91 million shares of the stock with an approximate value of $$64.86 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $$31.45 million in ABCL stock with ownership which is approximately 3.611%.
